WU-NK-101

WU-NK-101 · Wugen, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for WU-NK-101, covering 2025-04-15 to 2025-09-30. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) [Phase 1]